You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antibacterial nanoparticles as insecticide synergists and insect growth regulators for improved control of cockroach infestations

    SBC: APEX BAIT TECHNOLOGIES, INC.            Topic: NIAID

    PROJECT SUMMARY The prevalence of asthma in the United States is approximately 8% (andgt;25 million people). In African Americans, the prevalence is andgt;11%. A majority of asthma sufferers are sensitized to allergens, including those shed in the feces, saliva, and exuviae of cockroaches. Thus, exposure to cockroach infestation is recognized as both a significant risk factor for the development o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND

    SBC: ANDROSCIENCE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. Anti-Aging Mitochondrial Protein Therapy for Alzheimer?s Disease and Sarcopenia

    SBC: Gencia Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The decline of motor and cognitive function in aging finds an extreme manifestation in the form of sarcopenia and senile dementia, most commonly of the Alzheimer's type. Both are associated with mitochondrial dysfunction. In sarcopenia there is accumulation of mitochondrial DNA (mtDNA) deletions and loss of oxidative capacity in the muscle. In the Alzheimer's b ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. A novel wearable platform to assess cognitive-motor performance

    SBC: BIOSENSICS LLC            Topic: NIA

    ABSTRACT The recent shift in Alzheimer s diseaseADclinical research from clinical diagnosis toward the goal of developing neuroprotective therapies has highlighted the need for a robust and rapidly administered cognitive assessment tool capable of identifying individuals in the earliest stages of cognitive decline and measuring subtle changes in cognitive motor performance over timeIn this context ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A novel vaccine against vaginal Chlamydia trachomatis

    SBC: EPITOGENESIS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    PROJECT SUMMARYZika virus, an emerging flavivirus, is associated with severe clinical outcomes, including Guillain-Barré syndrome and birth defects. Transmission of Zika virus is primarily mosquito- borne. Mosquito salivary proteins are known to enhance infectivity and pathogenesis in Zika, dengue and West Nile viruses by modulating immune responses. This proposal seeks to develop a novel vaccine ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    SUMMARY Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed vaccines do not exist or are suboptimal. These pathogens are transmitted int ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. A novel vaccine/adjuvant for Streptococcus pneumoniae

    SBC: RxKinetix, Inc.            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Treatment for Acetominophen-Induced Liver Injury

    SBC: MITOTHERAPEUTIX, LLC            Topic: 300

    Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government